Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.0%

2 terminated out of 25 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

48%

12 trials in Phase 3/4

Results Transparency

63%

10 of 16 completed with results

Key Signals

10 with results89% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (4)
Early P 1 (1)
P 1 (2)
P 2 (4)
P 3 (9)
P 4 (3)

Trial Status

Completed16
Unknown3
Recruiting2
Terminated2
Withdrawn2

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT04371445Phase 4Recruiting

Dextenza in the Post-op Management of Vitreoretinal Surgeries

NCT05668455Phase 3RecruitingPrimary

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

NCT02128113Phase 2Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

NCT04690829Completed

Biomarkers in Ocular Inflammation and Uveitis

NCT04374656Completed

Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic

NCT05618730Phase 1Unknown

Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B

NCT04812951Early Phase 1Completed

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery

NCT05248139Not ApplicableUnknown

Safety and Effectiveness of Drop-free Small Incision Cataract Surgery

NCT03302273Not ApplicableCompleted

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03580473Phase 2CompletedPrimary

Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification

NCT01190878Phase 1CompletedPrimary

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

NCT01808547Phase 3CompletedPrimary

Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

NCT01576952Phase 3CompletedPrimary

Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

NCT02786901Phase 3Completed

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT03596723Phase 3TerminatedPrimary

KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

NCT03521791Phase 4Completed

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

NCT03408015Phase 4Withdrawn

Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

NCT03332342Not ApplicableCompleted

Closed Eye Neutrophils in Dry Eye Disease

NCT03597867Phase 3CompletedPrimary

PGE2 Levels in Patient Treated With NSAIDs

NCT00645671Phase 3CompletedPrimary

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

Scroll to load more

Research Network

Activity Timeline